40 Genes | 14-18 days TAT | MiniSeq and NextSeq (NGS) | Dry and Wet swabs
The CGX Screen is a Comprehensive Cancer Risk Assessment test designed to determine your risk of developing up to 8 cancer types. Armed with this critical genetic information as well as other medical and family facts, you can create a strategy to reduce your risk of developing one or more of these 8 prevalent cancers.
APC, ATM, BLM, BRCA1, BRCA2, CDH1, CDKN2A, FANCC, FH, HNF1A, HRAS, KIT, MEN1, MLH1, MSH2, MSH6, MUTYH, NF1, NF2, NSD1, PALB2, PHOX2B, PMS2, PTEN, RET, VHL, RUNX1, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, WT1, MAX, TMEM127 , APCEM
69 Genes | 14-18 days TAT | MiniSeq and NextSeq (NGS) | Dry and Wet swabs
It covers all cardiac and heart muscle related issues if they are genetically predisposed. The test report describes if the patient has any genetic mutation that can cause the heart-related issues i.e. Arrhythmia, Dilated Cardiomyopathy, Long and Short QT, etc. This is germline/screening testing. In other words, Cardiovascular Testing detects mutations associated with inherited cardiovascular diseases and sudden cardiac death to provide an exhaustive study of genes. It identifies the patient’s risk and risks for their close relatives. It helps physicians to make a treatment plan and lifestyle modifications for the patients.
ABCC9, ACAD9, ACADVL, ACTA1, ACTC1, ACTN2, AGK, AGL, APOA1, BAG3, CACNA1C, CAV3, CBL, COL1A1, COX15, CRYAB, CSRP3, DES, DMD, DOLK, DCS2, DSG2, DSP, EFEMP2, ELAC2, ELN, EMD, EPG5, EYA4, FBN1, FHL1, FKRP, FKTN, FLNC, FXN, GAA, GLA, HCN4, JUP, LAMP2, LMNA, MYBPC3, MYH7, MYL2, MYL3, NDUFAF2, PKP2, PLN, PRKAG2, PKP2, PLN, PRKAG2, RAF1, RBM20, RYR2, SCN5A, SCNN1A, SCNN1B, SGCD, SLC22A5, SLC25A4, SMAD4, TAZ, TCAP, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR, VCL
30 Genes | 14-18 days TAT | MiniSeq and NextSeq (NGS) | Dry and Wet swabs
MODY is a type of monogenic diabetes characterized by non-insulin-dependent diabetes and early onset (usually before age 35). Diabetes is a disorder that results in elevated blood glucose. Over time, the disorder can cause various health problems, including diseases of the heart, kidneys, eyes, and nervous system. There are different types of MODY. By finding out which type of MODY a person has, the most appropriate treatment for them can be determined. Knowing the type of MODY a person has also means we can advise them about how their diabetes will progress in the future. As it runs in families, it is important to advise other family members of their risk of inheriting it.
ABCC8 , BLK , CAP10, EIF2AK3 , FOXP3 , GATA6 , GCK , GLIS3 , GLUD1 , HADH , HNF1A , HNF1B , HNF4A , INS , INSR ,KCNJ11, KLF11 , NEUROD1 , NEUROG3 , PAX4 , PDX1 , PPARG , PTF1A , RFX6 , SLC16A1 , SLC2A2 , UCP2 , WFS1 , ZFP57 , SLC2A2 , UCP2 , WFS1 , ZFP57.
33 Genes | 10 days TAT | Quant Studio 12K Flex | Dry and Wet swabs
The physicians order this test before prescribing the medications to the patients. The test report describes how the patient’s DNA structure will metabolize the specific drugs.
We run all the medications in our PGx panel. We can also do drug-to-drug interactions. The doctor/patient can access the PGx report throughout their lifetime.
ACE, AGTR1, APOB, APOE, ATM, CACNA1C, COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, F2, F5, GRIK4, HFE, HLA-B, HTR2A, HTR2C, IFNL3, LDLR, MTHFR, OPRM1, RYR1, SLCO1B1, TPMT, UGT1A1, VKORC1
118 Genes | 14-18 days TAT | MiniSeq and NextSeq (NGS) | Dry and Wet swabs
This test examines an increased risk of developing neurocognitive disorders and detects both the diagnostic and risk factor genes for Alzheimer’s disease, Parkinson’s disease and dementia. These are the conditions that affect the brain and spinal cord.
PLCG2, TBP, TP53INP1, APOE, ANG, SOD1, TOR1A, PRNP, PSEN1, GCH1, PINK1, ARDBP, APTX, APP, PSEN2, PARK2, POLG, OPTN, FUS, SPAST, FIG4, SETX, MAPT, GRN, NOTCH3, LRRK2, ATM, CLU, PICALM, CR1, BIN1, CD33, MS4A4A, MS4A6E, CD2AP, EPHA1, ABCA7, CASS4, CELF1, FERMT2, INPP5D, MEF2C, NME8, PTK2B, SLC24A4, RIN3, SORL1, ZCWPW1, TREM2, ADAM10, PVRL2, ABI3, CSF1R, TRIP4, VPS35, SNCA, PRKRA, GBA, RAB39B, TMEM230, RAB7L1, VPS13C, PARK7, ATP13A2, PLA2G6, FBXO7, SYNJ1, DNAJC6, SCARB2, CHCHD2, PANK2, TAF1, GAK, ADORA1, EIF4G1, ATP6AP2, GIGYF2, HTRA2, VCP, PFN1, SQSTM1, UBQLN2, CHMP2B, NEFH, TBK1, NEK1, CHCHD10, TUBA4A, UNC13A, SARM1, C21orf2, EPHA4, LMNB1, DCTN1, HNRNPA1, HNRNPA2B1, VAPB, ALS2, TMEM106B, RAB38, CTSC, BTNL2, TOMM40, CLCN6, MARK2, MARK4, EP300, AKT1, SGTA, ELAVL1, THAP1, PRRT2, ANO3, TH, ATP1A3, DNMT1, ITM2B, TYROBP
67 Genes | 14-18 days TAT | MiniSeq and NextSeq (NGS) | Dry and Wet swabs
Redwood Labs offers a Comprehensive Pulmonology Panel. It is a 67 gene panel that includes assessment of non-coding variants. The genes on the panel have been carefully selected based on scientific literature, mutation databases, and our experience.
We provide customers with the most comprehensive clinical report available on the market. Clinical interpretation requires a fundamental understanding of clinical genetics and genetic principles. At Redwood Lab Services, our PhD molecular geneticists, medical geneticists, and clinical consultants prepare the clinical statement together by evaluating the identified variants in the context of the phenotypic information provided in the requisition form. Our goal is to provide clinically meaningful statements that are understandable for all medical professionals regardless of whether they have formal training in genetics
ABCA3, CCDC39, CCDC40, CFTR, CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, COLQ, CSF2RA, CSF2RB, DKC1, DNAAF1, DNAAF2, DNAH1, DNAH11, DNAH5, DNAI1, DNAI2, DNAL1, EDN3, EFEMP2, ELMOD2, ELN, FBLN5, FLCN, FOXF1, GAS8, GLRA1, HPS1, HPS4, ITGA3, LTBP4, MECP2, NAF1, NF1, NKX2-1, NME8, PARN, PHOX2B, PIH1D3, RAPSN, RET, RSPH3, RSPH4A, RSPH9, RTEL1, SCN4A, SCNN1A, SCNN1B, SERPINA1, SFTPA1, SFTPA2, SFTPB, SFTPC, SLC34A2, SLC6A5, SLC7A7, SMPD1, STAT3, TERC, TERT, TINF2, TSC1, TSC2, ZEB2
471 Genes | 14-18 days TAT | MiniSeq and NextSeq (NGS) | Dry and Wet swabs
The Immunodeficiency Panel analyzes genes that are associated with inherited disorders of the immune system. These genes were selected based on the available evidence to date for immunodeficiencies.
ACD, ACP5, ACTB, ADA, ADA2, ADAM17, ADAMTS13, ADAR, AICDA, AIRE, AK2, AP1S3, AP3B1, AP3D1, APOL1, ARMC4, ARPC1B, ATM, ATP6AP1, B2M, BACH2, BCL10, BCL11B, BLM, BLNK, BLOC1S3, BLOC1S6, BRCA2, BRIP1, BTK, C1QA, C1QB, C1QC, C1R, C1S, C2, C3, C4BPA, C5, C6, C7, C8A, C8B, C8G, C9, CARD11, CARD14, CARD9, CARMIL2, CASP10, CASP8, CAVIN1, CCBE1, CCDC103, CCDC114, CCDC39, CCDC40, CCDC65, CCNO, CD19, CD247, CD27, CD3D, CD3E, CD3G, CD40, CD40LG, CD46, CD55, CD59, CD70, CD79A, CD79B, CD81, CD8A, CDCA7, CEBPE, CENPF, CFAP298, CFB, CFD, CFH, CFHR1, CFHR2, CFHR3, CFHR4, CFHR5, CFI, CFP, CFTR, CHD7, CIITA, CLCN7, CLEC7A, CLPB, COG6, COLEC11, COPA, CORO1A, CR2, CREBBP, CSF2RA, CSF2RB, CSF3R, CTC1, CTLA4, CTPS1, CTSC, CXCR4, CYBA, CYBB, DCLRE1B, DCLRE1C, DDX58, DGKE, DHFR, DKC1, DNAAF1, DNAAF2, DNAAF3, DNAAF4, DNAAF5, DNAH1, DNAH11, DNAH5, DNAI1, DNAI2, DNAJC21, DNAL1, DNASE1L3, DNASE2, DNMT3B, DOCK2, DOCK8, DRC1, DTNBP1, ELANE, EPG5, ERCC2, ERCC3, ERCC4, ERCC6L2, ETV6, EXTL3, F11, F13A1, F13B, F5, F7, F8, F9, FAAP24, FADD, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FASLG, FAT4, FCGR3A, FCN3, FERMT3, FGA, FGB, FOXN1, FOXP3, FPR1, G6PC, G6PC3, G6PD, GAS8, GATA1, GATA2, GFI1, GINS1, GP1BA, GP1BB, GP9, GTF2H5, HAX1, HELLS, HPS1, HPS3, HPS4, HPS5, HPS6, HYDIN, HYOU1, ICOS, IFIH1, IFNAR2, IFNGR1, IFNGR2, IGHM, IGLL1, IKBKB, IKZF1, IL10, IL10RA, IL10RB, IL12RB1, IL17F, IL17RA, IL17RC, IL1RN, IL2, IL21, IL21R, IL2RA, IL2RG, IL36RN, IL7R, INO80, INSR, INVS, IRAK1, IRAK4, IRF2BP2, IRF3, IRF7, IRF8, ISG15, ITCH, ITGAM, ITGB2, ITK, JAGN1, JAK1, JAK2, JAK3, KDM6A, KMT2D, KRAS, LAMTOR2, LAT, LCK, LIG1, LIG4, LPIN2, LRBA, LRRC6, LRRC8A, LYST, MAGT1, MALT1, MAN2B1, MANBA, MAP3K14, MASP1, MASP2, MBL2, MC2R, MCM4, MEFV, MKL1, MLPH, MOGS, MPL, MPO, MRE11, MS4A1, MSH6, MSN, MTHFD1, MVK, MYD88, MYH9, MYO5A, MYSM1, NBAS, NBN, NCF1, NCF2, NCF4, NCSTN, NFAT5, NFKB1, NFKB2, NFKBIA, NHEJ1, NHP2, NKX2-5, NLRC4, NLRP1, NLRP12, NLRP3, NME8, NOD2, NOP10, NRAS, NSMCE3, OFD1, ORAI1, OSTM1, OTULIN, PALB2, PARN, PCCA, PCCB, PEPD, PGM3, PI4KA, PIGA, PIH1D3, PIK3CD, PIK3R1, PLCG2, PLEKHM1, PLG, PMM2, PMS2, PNP, POLA1, POLE, POLE2, PRF1, PRKCD, PRKDC, PROC, PROS1, PSENEN, PSMB8, PSTPIP1, PTEN, PTPRC, RAB27A, RAC2, RAD50, RAD51C, RAG1, RAG2, RANBP2, RASGRP1, RBCK1, RBM8A, RECQL4, RELB, RFX5, RFXANK, RFXAP, RHOH, RMRP, RNASEH2A, RNASEH2B, RNASEH2C, RNF168, RNF31, RNU4ATAC, RORC, RPGR, RPL11, RPL15, RPL26, RPL35A, RPL36, RPL5, RPS10, RPS15, RPS15A, RPS17, RPS19, RPS24, RPS26, RPS27A, RPS28, RPS29, RPS7, RPSA, RSPH1, RSPH3, RSPH4A, RSPH9, RTEL1, RUNX1, SAMD9, SAMD9L, SAMHD1, SBDS, SEMA3E, SERPING1, SH2D1A, SH3BP2, SKIV2L, SLC29A3, SLC35A1, SLC35C1, SLC37A4, SLC39A4, SLC46A1, SLC7A7, SLX4, SMARCAL1, SMARCD2, SNX10, SP110, SPAG1, SPINK5, SRP54, SRP72, STAT1, STAT2, STAT3, STAT5B, STIM1, STK4, STN1, STX11, STXBP2, TAP1, TAP2, TAPBP, TAZ, TBK1, TBX1, TCF3, TCIRG1, TCN2, TERC, TERT, TFRC, THBD, TICAM1, TINF2, TIRAP, TLR3, TMC6, TMC8, TMEM173, TNFAIP3, TNFRSF11A, TNFRSF13B, TNFRSF13C, TNFRSF1A, TNFRSF4, TNFSF11, TNFSF12, TPP1, TPP2, TRADD, TRAF3, TRAF3IP2, TREX1, TRNT1, TTC37, TTC7A, TYK2, UNC119, UNC13D, UNC93B1, UNG, USB1, USP18, VPS13B, VPS45, WAS, WDR1, WIPF1, WRAP53, XIAP, XK, ZAP70, ZBTB24, ZMYND10, ZNF341
262 Genes | 14-18 days TAT | MiniSeq and NextSeq (NGS) | Dry and Wet swab7
ABCC9, ACTA2, ACTC1, ACTN2, ACVRL1, ADAMTS2, AKAP9, ALDH18A1, ALMS1, ALPK3, ANK2, ANKRD1, APOB, ATP6V0A2, ATP6V1E1, ATP7A, B3GALT6*, B3GAT3, B4GALT7, BAG3, BGN, BMPR2, BRAF, CACNA1C, CACNA2D1, CACNB2, CALM1^, CALM2, CALM3, CASQ2, CAV1, CAV3, CBS, CHRM2, CHST14, COL11A1, COL11A2, COL12A1, COL1A1, COL1A2, COL2A1, COL3A1, COL5A1, COL5A2, COL9A1, COL9A2, COL9A3, CRYAB, CSRP3, CTNNA3, DES, DMD, DOLK, DSC2, DSE, DSG2, DSP, DTNA, EFEMP2, EIF2AK4, ELN, EMD, ENG, EYA4, FBLN5, FBN1, FBN2, FHL1, FKBP14, FKRP*, FKTN, FLNA, FLNC, GAA, F9, GATA4, GATA5^, GATA6, GATAD1, GDF2, GJA5, GLA, GNB5, GPD1L, HCN4, HFE, HRAS*, ILK, JPH2, JUP, KCNA5, KCND3, KCNE1, KCNE1L, (KCNE5), KCNE2, KCNE3, KCNH2, (HERG), KCNJ2, KCNJ5, KCNJ8, KCNK3, KCNQ1, KRAS, LAMA4, LAMP2, LDB3, LDLR, LDLRAP1, LMNA, LOX, LRRC10, LTBP4, MAP2K1, MAP2K2, MAT2A, MED12, MFAP5, MIB1, MURC, MYBPC3, MYH11, MYH6, MYH7, MYL2, MYL3, MYL4, MYLK, MYLK2, MYOZ2, MYPN, NEBL, NEXN, NKX2-5, NOTCH1, NRAS, PCSK9, PDLIM3, PKP2, PLN, PLOD1, PPA2, PRDM16, PRDM5, PRKAG2, PRKG1, PTPN11, PYCR1, RAF1, RANGRF, RASA1, RBM20, RIN2, RIT1, RYR2, SCN10A, SCN1B^, SCN2B, SCN3B, SCN4B, SCN5A, SGCD, SHOC2, SKI, SLC2A10, SLC39A13, SMAD2, SMAD3, SMAD4, SMAD9, SNTA1, SOS1, TAZ^, TBX20^, TCAP, TECRL, TGFB2, TGFB3, TGFBR1, TGFBR2, TMEM43, TMPO, TNNC1, TNNI3, TNNT2, TNXB, TOR1AIP1, TPM1U, TRDN, TRPM4, TTN, TTR, TXNRD2, VCL, ZNF469
CCDC39, CCD40, CFTR, CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, COLQ, CSF2RA, CSF2RB, DKC1, DNAAF1, DNAAF2, DNAH1, DNAH11, DNAH5, DNAI1, DNAI2, DNAL1, EDN3, EFEMP2, ELMOD2, ELN, FBLN5, FLCN, FOXF1, GAS8, GLRA1, HPS1, HPS4, ITGA3, LTBP4, MECP2, NAF1, NF1, NKX2-1, NME8, PARN, PHOX2B, PIH1D3#, RAPSN, RET, RSPH3, RSPH4A, RSPH9, RTEL1, SCN4A, SCNN1A, SCNN1B, SERPINA1, SFTPA1, SFTPA2, SFTPB, SFTPC, SLC34A2, SLC6A5, SLC7A7, SMPD1, STAT3, TERC, TERT, TINF2, TSC1, TSC2, ZEB2
The routine EEG is a test that detects abnormalities in your brain waves, or in the electrical activity in your brain waves as well cardiological and psychological activity. Using electrodes placed on the scalp, an EEG continuously monitors your brain waves to detect and graph electrical charges that result from the activity of your brain cells to find possible causes or associations to your symptoms. Symptoms requiring this test may include seizures, Alzheimer’s, Narcolepsy, TIA/TBI, and other psychoses.
The Ambulatory EEG test is similar to the standard EEG test that measures neurological, cardiological, and psychological activity simultaneously from the comfort of your home. The patient is free to go through their daily routine while the device continuously records all brain wave activities as well as patient behavior during their test. This test is available in 72-hour, 96-hour, 120-hour, or custom durations. Symptoms requiring this test may be unexplained seizure episodes, dizziness, altered awareness, TIA/TBI, and is used when a standard EEG is non-diagnostic.
Intermittent monitoring is used for tracking a patient’s response to treatment for seizures and other disorders.
RPP (Respiratory Pathogen Panel) is an easy-to-use close tube nasal swab system that significantly reduces contamination risks. Collected swab samples are used to identify both RNA and DNA from 43 different viral and bacterial targets from individuals with clinical signs and symptoms of a respiratory tract infection. Molecular testing utilizes PCR (Polymerase Chain Reaction) technology, allowing small quantities of nucleic acid to be amplified into detectable levels. Test result data helps the practitioner select appropriate treatment.
UTI (Urinary Tract Infection) is collected from urine samples. It is used to identify both RNA and DNA from 43 different bacterial targets from individuals with clinical signs and symptoms of an infection. This test includes sexually transmitted infection testing. Molecular testing utilizes PCR (Polymerase Chain Reaction) technology, allowing small quantities of nucleic acid to be amplifies into detectable levels. Test result data helps the practitioner select appropriate treatment.
RT-PCR (reverse transcription-polymerase chain reaction) is the most sensitive technique for mRNA detection and quantitation currently available. PCR tests are considered a gold standard by the CDC for diagnosing COVID-19 because of their sensitivity and specificity.
There are many potential reasons why a medical professional may order a urine drug screen (UDS) for a patient. A primary care physician (PCP) may order a UDT if it’s suspected that a patient may have a substance abuse problem. An emergency room doctor may order a UDT if a patient is acting erratically. Drug and alcohol rehabilitation centers may require participants in inpatient or outpatient programs to have periodic tests. Additional reasons could include: Monitoring a patient’s medication adherence, and screening for possible drug interactions
A primary care physician (PCP) may order a UDT if it’s suspected that a patient may have a substance abuse problem. An emergency room doctor may order a UDT if a patient is acting erratically. Drug and alcohol rehabilitation centers may require participants in inpatient or outpatient programs to have periodic tests. Additional reasons could include: Monitoring a patient’s medication adherence, Screening for possible drug interactions.